오라 바이오사이언시스(AURA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.64 (+0.76%), 시가총액 $0.85B, 52주 최저~최고 $4.97 ~ $8.90.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company wa
오라 바이오사이언시스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오라 바이오사이언시스의 현재 주가는 $6.64 (+0.76%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오라 바이오사이언시스의 시가총액은 약 $0.85B입니다.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors